By Jacob Gronholt-Pedersen COPENHAGEN (Reuters) -Four patients in Denmark, who experienced vision loss after using Novo ...

For a limited time, patients with a prescription can get a steep discount on the popular medications, as long as they’re ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

Novo Nordisk cuts Wegovy's price and commits fully to its upcoming weight-loss pill to stay competitive in the fast-growing ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...

Novo revealed Monday that the self-pay cost for the two lowest dosages of Wegovy and Ozempic will be $349 per month, down ...

This prompted an unusual and bitter bidding war, where Doustdar goaded Pfizer to raise its bid during a press conference in the Oval Office. In the end, Pfizer won by matching Novo’s $10bn offer, as ...

Novo Nordisk A/S remains attractive with strong cash flow and robust pipeline. Click here to read why NVO stock is a Buy.